Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;31(8):1383-4.
doi: 10.3174/ajnr.A2170. Epub 2010 Jun 10.

Temozolomide (Temodar)

J R Wesolowski  1 , P Rajdev, S K Mukherji
Affiliations

Temozolomide (Temodar)

J R Wesolowski et al. AJNR Am J Neuroradiol. 2010 Sep.

Abstract

Temozolomide, an oral alkylating agent, is a commonly used medicine in the treatment of anaplastic astrocytoma and glioblastoma multiforme. This paper will present the mechanism of action as well as the clinical role for this chemotherapeutic drug.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Schematic illustration of the proposed mechanism of temozolomide. Temozolomide is converted intracellularly into MTIC, which methylates DNA. Cellular repair mechanisms cannot adjust, resulting in DNA nicks and ultimately apoptosis.
Fig 2.
Fig 2.
Imaging findings associated with a good response to treatment in a patient with recurrent astrocytoma. Fluid-attenuated inversion recovery (A) and postcontrast T1-weighted sequences (B) demonstrate a postsurgical cavity with associated mild surrounding T2 prolongation and lack of enhancement. C and D, Follow-up examination 18 months later shows no disease progression.
See this image and copyright information in PMC

References

    1. Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 2009;64:647–55 - PubMed
    1. Colvin M. Alkylating agents and platinum antitumor compounds. In: Kufe DW, Frei E, Holland JF, et al. eds. Holland-Frei Cancer Medicine. 8th ed. Shelton, Connecticut: People's Medical Publishing House; 2010
    1. Newlands ES, Stevens MF, Wedge SR, et al. . Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35–61 - PubMed
    1. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5:144–51 - PubMed
    1. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6:2585–97 - PubMed

MeSH terms